|

CSL300 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Clazakizumab

Pipeline

Phase 2/3: 1

Top Sponsors

  • CSL Behring1

Indications

  • Atherosclerotic Cardiovascular Disease in Patients With ESKD1
  • End Stage Kidney Disease1
  • Atherosclerotic Cardiovascular Disease1
  • Heart Disease1
  • Diabetes1

Decatur, Alabama1 trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Nephrology of North Alabama

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.